Vifor Pharma AG is a pharmaceutical enterprise dedicated to the research, production, and global commercialization of medicines, with operations spanning Switzerland, the rest of Europe, the United States, and other international markets. Its current product offerings include Ferinject/Injectafer, an injectable ferric carboxymaltose solution for treating iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex specifically formulated for infants, children, adolescents, and pregnant individuals experiencing iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) targeting symptomatic anemia associated with chronic kidney disease (CKD). The company's portfolio also features Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose formulation used to address iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder developed for managing hyperphosphatemia in adult CKD patients undergoing dialysis.